Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    VolitionRx

    MCap

    USD76m

    Last close

    USD0.81

    ▲ 0.14 (20.90%)

    Canyon Resources

    MCap

    AUD262m

    Last close

    AUD0.19

    ▲ 0.02 (12.12%)

    Immix Biopharma

    MCap

    USD51m

    Last close

    USD1.82

    ▲ 0.12 (7.06%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Executive interview – VolitionRx announces second quarter 2017 financial results

Executive interview – VolitionRx announces second quarter 2017 financial results

Cameron Reynolds, president and CEO of VolitionRx explains: “We have had numerous highlights this quarter, with strong progress being made on many fronts. I am delighted with the growing strength of new talent in our team, especially the growth in our Research & Development team in Belgium. We are also fortunate to be working with institutions and individuals who have brilliant reputations. We continue to announce large trials, such as the recent signing of a 13,500-patient US trial in colorectal cancer. We believe that this most recently announced trial, with a cost to us of only $3m, represents an exceptional value for our money. We look forward to achieving additional milestones in the upcoming quarters and sharing further exciting news.”

< Previous
Next >

You may also be interested in these:

TMT

VEON – executive interview with CFO Joop Brakenhoff

TMT

VEON – executive interview with CEO Kaan Terzioğlu

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free